Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2017

01-02-2017 | Clinical trial

Strut-adjusted volume implant (SAVI) brachytherapy-based accelerated partial breast irradiation (APBI) in African American women

Authors: Amir Isbell, Jacquelyn Dunmore-Griffith, Olubunmi Abayomi

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Login to get access

Abstract

Purpose

To examine the clinical outcomes of postmenopausal African American (AA) women treated with strut-adjusted volume implant brachytherapy-based accelerated partial breast irradiation for early-stage node-negative breast cancer.

Methods

From January 2011 through April 2015, a total of 50 AA patients, meeting criteria to receive APBI as defined by the National Surgical Adjuvant Breast and Bowel Project B-39 (NASBP B-39), completed treatment with the SAVI breast brachytherapy device at Howard University Hospital.

Results

4% ipsilateral breast tumor recurrence and 2% breast cancer-specific mortality was observed. Median follow-up has been 3.8 years with a range of 0.29–4.69 years. Dosimetry parameters yielded a median V90 of 96.22% (range 77.86–105.00%), a median V150 of 31.27 cm3 (range 23.30–49.15 mL), and a median V200 of 14.53 cm3 (range 5.92–19.38 mL). Cosmesis was excellent. There were no infections, persistent seromas, fat necrosis, or telangiectasias observed to date.

Conclusions

This study is the first study to describe the use of SAVI as APBI in an exclusively AA population. This study has demonstrated excellent local control in appropriately selected patients, similar clinical outcomes to the general population, and good to excellent cosmesis in AA women to date.
Literature
1.
McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ (2015) Effects of age on the detection and management of breast cancer. Cancers (Basel) 7(2):908–929CrossRef
2.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefPubMed
3.
Byers T, Wender RC, Jemal A, Baskies AM, Ward EE, Brawley OW (2016) The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections. CA Cancer J Clin 66(5):359–369CrossRefPubMed
4.
Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med 347:1233–1241CrossRefPubMed
5.
Veronesi U, Cascinelli N, Mariani L et al (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New Engl J Med 347:1227–1232CrossRefPubMed
6.
Fowble B (1999) Ipsilateral breast tumor recurrence following breast conserving surgery for early stage invasive cancer. Acta Oncol Suppl 13:9–17CrossRef
7.
Veronesi U, Luini A, del Vecchio M et al (1993) Radiotherapy after breast preserving surgery in women with localized cancer of the breast. N Engl J Med 328:1587–1591CrossRefPubMed
8.
Fowble B, Soli LJ, Schultz DJ et al (1990) Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic finding from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys 19:833–842CrossRefPubMed
9.
Polgár C, Fodor J, Major T, Németh G, Lövey K, Orosz Z, Sulyok Z, Takácsi-Nagy Z, Kásler M (2007) Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma—5-year results of a randomized trial. Int J Radiat Oncol Biol Phys 69(3):694–702CrossRefPubMed
10.
Recht A, Ancukiewicz M, Alm El-Din MA, Lu XQ, Martin C, Berman SM, Hirsch AE, Kachnic LA, Katz A, MacDonald S, Nedea EA, Stevenson MA, Powell SN, Taghian AG (2009) Lung dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation using three-dimensional conformal radiotherapy. J Clin Oncol 27(24):3887–3893CrossRefPubMed
11.
Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE (2009) Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 75(5):1290–1296CrossRefPubMed
12.
Gupta S, Scanderbeg DJ, Kamrava M, Yashar CM (2009) Unexpected toxicity in a patient treated with 3D conformal accelerated partial breast radiotherapy. Brachytherapy 8(2):207–209CrossRefPubMed
13.
Yashar CM et al (2011) Initial clinical experience with the strut-adjusted volume implant (SAVI) breast brachytherapy device for accelerated partial-breast irradiation (APBI): first 100 patients with more than 1 year of follow-up. Int J Radiat Oncol Biol Phys 80(3):765–770CrossRefPubMed
14.
Scanderbeg D, Yashar C, Rice R et al (2009) Clinical implementation of a new HDR brachytherapy device for partial breast irradiation. Radiother Oncol 90:36–42CrossRefPubMed
15.
16.
Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, Whelan TJ, White J, Wo JY, Harris JR (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 74(4):987–1001CrossRefPubMed
17.
18.
19.
Iqbal J, Ginsburg O, Rochon PA et al (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173CrossRefPubMed
20.
Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Trinh QD, Hu JC, Nguyen PL (2014) Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120(10):1532–1539CrossRefPubMed
21.
Lautner M, Lin H, Shen Y et al (2015) Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg. 150(8):778–786CrossRefPubMedPubMedCentral
22.
Pierce L, Fowble B, Solin LJ, Schultz DJ, Rosser C, Goodman RL (1992) Conservative surgery and radiation therapy in black women with early stage breast cancer. Patterns of failure and analysis of outcome. Cancer 69(11):2831–2841CrossRefPubMed
23.
Roach M 3rd, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, Hart R, Henderson IC (1997) Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am 3(2):107–112PubMed
24.
Newman LA, Kuerer HM, Hunt KK, Singh G, Ames FC, Feig BW, Ross MI, Taylor S, Singletary SE (1999) Local recurrence and survival among black women with early-stage breast cancer treated with breast-conservation therapy or mastectomy. Ann Surg Oncol 6(3):241–248CrossRefPubMed
25.
Connor CS, Touijer AK, Krishnan L, Mayo MS (2000) Local recurrence following breast conservation therapy in African-American women with invasive breast cancer. Am J Surg 179(1):22–26CrossRefPubMed
26.
Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG (2008) Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer 113(9):2565–2574CrossRefPubMed
27.
Perez CA (2010) Breast conservation therapy in patients with stage T1-T2 breast cancer: current challenges and opportunities. Am J Clin Oncol 33(5):500–510CrossRefPubMed
28.
Edwards-Bennett SM, Jacks LM, McCormick B, Zhang Z, Azu M, Ho A, Powell S, Brown C (2011) Patterns of utilization of adjuvant radiotherapy and outcomes in black women after breast conservation at a large multidisciplinary cancer center. Int J Radiat Oncol Biol Phys 80(4):1102–1108CrossRefPubMed
29.
White J, Winter K, Kuske RR, Bolton JS, Arthur DW, Scroggins T, Rabinovitch RA, Kelly T, Toonkel LM, Vicini FA, McCormick B (2016) Long-term cancer outcomes from study NRG oncology/RTOG 9517: a phase 2 study of accelerated partial breast irradiation with multicatheter brachytherapy after lumpectomy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 95(5):1460–1465CrossRefPubMedPubMedCentral
30.
Vicini FA, Antonucci JV, Wallace M, Gilbert S, Goldstein NS, Kestin L, Chen P, Kunzman J, Boike T, Benitez P, Martinez A (2007) Long-term efficacy and patterns of failure after accelerated partial breast irradiation: a molecular assay-based clonality evaluation. Int J Radiat Oncol Biol Phys 68(2):341–346. Epub 2007 Feb 15CrossRefPubMed
31.
Dodwell DJ, Dyker K, Brown J, Hawkins K, Cohen D, Stead M, Ash D (2005) A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol) 17(8):618–622CrossRef
32.
Polgar C, Major T, Fodor J et al (2004) High-dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast-conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys 60:1173–1181CrossRefPubMed
33.
Wallace M, Martinez A, Mitchell C, et al (2009) Phase I/II study evaluating early tolerance in breast cancer patients undergoing accelerated partial breast irradiation treated with the mammosite balloon breast brachytherapy catheter using a 2-day dose schedule. Int J Radiat Oncol Biol Phys
34.
Cuttino L, Heffernan J, Vera R et al (2011) Association between maximal skin dose and breast brachytherapy outcome: a proposal for more rigorous dosimetric constraints. Int J Radiat Oncol Biol Phys 81(3):e173–e177CrossRefPubMed
35.
Shah C, Badiyan S, Ben Wilkinson J, Vicini F, Beitsch P, Keisch M, Arthur D, Lyden M (2013) Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite(®) breast brachytherapy registry trial. Ann Surg Oncol 20:3279–3285CrossRefPubMed
36.
Cuttino LW, Arthur DW, Vicini F, Todor D, Julian T, Mukhopadhyay N (2014) Long-term results from the Contura multilumen balloon breast brachytherapy catheter phase 4 registry trial. Int J Radiat Oncol Biol Phys 90:1025–1029CrossRefPubMed
37.
Strnad V, Hildebrandt G, Pötter R, Hammer J, Hindemith M, Resch A, Spiegl K, Lotter M, Uter W, Bani M et al (2011) Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys 80:17–24CrossRefPubMed
38.
Arthur DW, Winter K, Kuske RR, Bolton J, Rabinovitch R, White J, Hanson WF, Wilenzick RM, McCormick B (2008) A Phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys 72:467–473CrossRefPubMedPubMedCentral
39.
King TA, Bolton JS, Kuske RR, Fuhrman GM, Scroggins TG, Jiang XZ (2000) Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T(is,1,2) breast cancer. Am J Surg 180:299–304CrossRefPubMed
40.
Polgár C, Major T, Fodor J, Sulyok Z, Somogyi A, Lövey K, Németh G, Kásler M (2010) Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol 94:274–279CrossRefPubMed
41.
Rabinovitch R, Winter K, Kuske R, Bolton J, Arthur D, Scroggins T, Vicini F, McCormick B, White J (2014) RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma–year-5 toxicity and cosmesis. Brachytherapy 13:17–22CrossRefPubMed
42.
Shah C, Antonucci JV, Wilkinson JB, Wallace M, Ghilezan M, Chen P, Lewis K, Mitchell C, Vicini F (2011) Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol 100:210–214CrossRefPubMed
43.
Ott OJ, Hildebrandt G, Pötter R, Hammer J, Hindemith M, Resch A, Spiegl K, Lotter M, Uter W, Kortmann RD et al (2011) Accelerated partial breast irradiation with interstitial implants: risk factors associated with increased local recurrence. Int J Radiat Oncol Biol Phys 80:1458–1463CrossRefPubMed
44.
Ott OJ, Hildebrandt G, Pötter R, Hammer J, Lotter M, Resch A, Sauer R, Strnad V (2007) Accelerated partial breast irradiation with multi-catheter brachytherapy: local control, side effects and cosmetic outcome for 274 patients. Results of the German-Austrian multi-centre trial. Radiother Oncol 82:281–286CrossRefPubMed
45.
Antonucci JV, Wallace M, Goldstein NS, Kestin L, Chen P, Benitez P, Dekhne N, Martinez A, Vicini F (2009) Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys 74:447–452CrossRefPubMed
46.
Silverstein MJ, Fastner G, Maluta S, Reitsamer R, Goer DA, Vicini F, Wazer D (2014) Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 2–TARGIT. Ann Surg Oncol 21:3793–3799CrossRefPubMedPubMedCentral
Metadata
Title
Strut-adjusted volume implant (SAVI) brachytherapy-based accelerated partial breast irradiation (APBI) in African American women
Authors
Amir Isbell
Jacquelyn Dunmore-Griffith
Olubunmi Abayomi
Publication date
01-02-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4091-6

Other articles of this Issue 1/2017

Breast Cancer Research and Treatment 1/2017 Go to the issue

Epidemiology

Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up

Clinical trial

Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02)

Epidemiology

Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa

Preclinical study

PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients

Clinical trial

Diagnostic performance of tomosynthesis and breast ultrasonography in women with dense breasts: a prospective comparison study

Epidemiology

Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits